https://retractionwatch.com/2020/04/12/elsevier-investigating-hydroxychloroquine-covid-19-paper/

The first HCQ study has some extreme problems — the data is strangely censored, the ‘14-day follow up’ period is longer than the time between study approval and the manuscript appearing in public (and the data for the follow-up was unaccountably not made available), the control group and the intervention group were from different sites, the actual testing of the viral load was untrustworthy, the sample size is astonishingly small, and so on. Under normal circumstances, a journal would instantly desk-reject this paper. Instantly.
https://medium.com/@jamesheathers/hurry-dont-rush-e1aee626e733